Please ensure Javascript is enabled for purposes of website accessibility

Why DexCom, Inc. Shares Fell 21% Today

By Todd Campbell - Feb 8, 2016 at 2:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A Wall Street downgrade is weighing down shares.

Image source: DexCom.

What: After investment firm Robert W. Baird downgraded the stock from outperform to neutral, shares in DexCom (DXCM 3.27%) were down 21.5% at 2:00 p.m. ET today.

So what: Despite reporting at the J.P. Morgan healthcare conference last month that unaudited revenue from the sale of DexCom's continous glucose monitors jumped 54% to approximately $400 million in 2015, the company's shares have fallen 40.5% this year.

Contributing to investors' concern is DexCom's spending plans.

DexCom plans to build a new factory, expand in the EU, and funnel more money into R&D this year, and that means the company's operating margin may take a short-term hit in 2016. As a result, industry watchers have reduced their EPS forecast to a loss of $0.05 in 2016, down from a gain of $0.20 90 days ago.

Now what: Although spending may weigh down profit this year, the global diabetes market is expected to climb to 642 million people in 2040 from 415 million people today, and that should mean a healthy trajectory for future sales -- especially if DexCom can successfully negotiate Medicare and Medicaid reimbursement and make headway into the type 2 diabetes market.

At the J.P. Morgan healthcare conference, DexCom forecast sales of $540 million to $565 million in 2016, up at least 35% from last year. 

That projection suggests a slowing in year-over-year growth, but it's still healthy enough to make this company intriguing, particularly given that Baird's new $74 price target is still nicely higher than shares are trading today. 

Overall, investors might want to consider stepping up and buying shares on this sell-off, because DexCom has seen a tenfold increase in revenue since 2011, yet it's only penetrated a small slice of this massive addressable market. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DexCom, Inc. Stock Quote
DexCom, Inc.
$77.67 (3.27%) $2.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.